<DOC>
	<DOCNO>NCT02446743</DOCNO>
	<brief_summary>The purpose/aim study ass 1 ) long-term persistence ( 4 7.5 year last dose ) bactericidal activity follow primary vaccination rMenB+OMV NZ adolescent [ previously participate parent study V72_41 ( NCT0142384 ) V72P10 ( NCT00661713 ) ] 2 ) kinetics immune response follow booster vaccination rMenB+OMV NZ</brief_summary>
	<brief_title>Combined Study - Phase 3b MenB Long Term Persistence Adolescents</brief_title>
	<detailed_description>After subject ( Groups A B ) Canada Australia complete study , interim analysis primary secondary immunogenicity objective perform . Follow subject ( Group A ) parent study V72_41 ( NCT0142384 ) analyze ) antibody persistence approximately 4 year follow 2 dose primary series ii ) immune response 3 , 7 30 day third dose ( booster ) rMenB+OMV NZ . Canadian Australian vaccine naïve subject ( Group B ) analyze immune response 30 day first dose , 3 , 7 30 day second dose rMenB+OMV NZ . Subjects Group B ( naïve subject ) randomize two different blood draw schedule accord 1:1 ratio .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criterion followon subject : Individuals participate Study V72_41 V72P10 complete vaccination rMenB+OMV NZ accord 2dose schedule Inclusion Criterion naïve subject : Individuals 15 21 year age day inform consent assent applicable ( accord subject 's age ) subject enrol site participate Study V72_41 . 17 24 year age day inform consent assent applicable ( accord subject 's age ) subject enrol site participate Study V72P10 . Inclusion Criteria subject : Individuals voluntarily give write informed consent nature study explain accord local regulatory requirement , prior study entry . Individuals comply study procedure include followup . Males Or Females nonchildbearing potential Or Females childbearing potential use effective birth control method . Exclusion Criteria subject Exclusion Criterion followon subject : • Received third dose Meningococcal group B vaccine prior enrolment study . Exclusion Criterion naïve subject : • Received Meningococcal group B vaccines prior enrolment study . Exclusion Criteria subject : Progressive , unstable uncontrolled clinical condition . Hypersensitivity , include allergy , component vaccine medical equipment whose use foreseen study . Abnormal function immune system . Received immunoglobulin blood product within 180 day prior informed consent assent applicable ( accord subject 's age ) . Received investigational nonregistered medicinal product within 30 day prior informed consent assent applicable ( accord subject 's age ) . Study personnel immediate family household member . Any clinical condition , opinion investigator , might pose additional risk subject due participation study . Positive result urine pregnancy test perform study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Central Nervous System Diseases</keyword>
</DOC>